Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great Post!
I have the same thesis and have bought a sizable amount. I think we will see a gradual up-tick in earnings over the next year and an improved bottom line. Cash flow should dramatically increase come 2017 with the lawsuit payments ending.
My Point of view:
The company did an ok quarter.
- Minor growth in revenue over last year and slight growth over the prior Q (2.1M last Q; 2.3M this one - showing a nice increase on a 6 month basis -->4.55M vs. 3.90M)
- Profitability has improved over the last Q and is actually showing an eps figure (although slightly lower than last year but better on a 6 month basis)
- Cash increased from last Q (918k vs now 1.11M)
- positive Cash flow from operations of 185k
- Legal settlement payable continues to get paid down and should be almost done by start of 2017 which should drastically improve cash flow and give the company more runway.
- Restricted cash is showing a very healthy balance as at June 31st (this is the cash that is held on the prepaid cards) and could be a good indication of future Q's as the company earns more the more the cards are used and the larger the amounts that are held. (10.35M this Q vs. 7.6M last Q)
Plasma is currently the main source of earnings for the company (unlike some of the past years where it was "lumpy" caused by other "random sources" (pharma, promotional compaigns, etc..). Although it will be nice to see growth in revenue the company appears to be realigning with its priorities of focusing on the main revenue source in the plasma centers and being a leader in this payment space (I like the consistency of the revenue and also read articles that the plasma industry is expected to double over the next 5 years which should be great for 3PEa)
Management is focusing on growing the business, adding new plasma centers and expanding its offerings. We all would like to see a PR but it will take time as they want a "story" to tell. No point spending money on things they don't deem to be a necessity. I know we all would like more transparency (I would like more PR's too but know it will come in time). The company has a plan and is getting back on track after being derailed with that lawsuit and the investment community had too high of expectations after a skewed quarter in 2014 due to revenue recognition.
I'm tucking my 3Pea shares away and will wait patiently to let it unfold.
just my 2 cents.
Cheers,
E.
I don't see it as that big of an issue. There isn't a massive outbreak in the US and really plasma centers simply have to add screens for the virus (they always screen for other things anyways when you give blood I don't see the testing for another item being that big of an issue). The people that regularly give plasma will continue to do so and the payments will continue to get made through the use of Paysign, thus making 3Pea money.
The plasma centers have been growing rapidly in the US and the company keeps adding clients. Other than these seller i'm not too concerned. I'm happy to pick up at these levels but am running out of capacity.
The way I see it - people tainted this company with a bad brush because of:
- The legal settlement which based on my discussion with the company and my understanding of the event had been a legal battle that was ongoing for quite awhile. They could have won the case but would have had to expend more time and money fighting it than the settlement amount required. A non-issue now. Its resolved and is a one time event that does not concern me too much as I trust the current management team.
- The Cyclical nature of the earnings and expectations that were set with that huge Q4 in 2014. This has tappered off - was largely do to non-plasma card projects where revenue was recognized at the end or projects. The company has narrowed their focus which is for the best. I am in the investment business and we like companies that focus on the most profitable revenue stream and drive the one that will bring the most success. When a company tries to do "everything" it is less effective. Plasma earnings are stable and does not give big cyclical revenue cycles (other than seasonality). The company is drastically growing their presence in this sector and the sector itself is growing fast (meaning even their current clients are opening new centers and adding to their growth). I would put their market share in the plasma donor space at close to 15-20% which is pretty good. I would expect them to grow this share. The margin improvement and lower expenses is great.
People have sold this company off yet I feel the underlying fundamentals are still there. By early 2017 no more legal settlement payments, reasonable margins will continue, growth will persist and we will have ourselves a nice little company. 2015 put this company in the dog house, 2016 should help shed some better light on what can reasonably be expected and hopefully get them back on people's "good side". Huge value here given future expectations and annualized earnings ie. by even taking Q1 which is the lowest Quarter and annualizing it (2.2*4=8.8M) we are sitting below 1x Price to sales which is exceptionally low...
Overall good Q:
- significant increase in revenue by 36.4% yoy
- improved gross margins (35% to 46%)
- decrease in SG&A expenses despite increase in revenue
- profitable vs loss last year
I like the improvement.
E.
No idea who it is but I picked up 5k shares at an average of 0.1729.
I'll look to add more it it drops any further this is selling for no good reason.
I loaded up with "more sizable" trades when it initially dipped below 0.20.. my current orders are all very opportunistic buy's with small left over cash.. I have some orders from 0.19 all the way down to 0.16 (just incase).
I've got plenty to begin with! I'm ready for the next year or so when I believe things will start improving (at these valuations I may decide to buy a bit more...it won't last forever at this fire sale price)
I would take out that 0.2 but i'm quite set on keeping my bottom feeder limit order in at 0.189 and 0.19...
Pretty big volume and jump to 0.30 at the open, the Ask moved up alot. Was hoping to get more under 0.20!
Someone wanted in...
I've got some small buy orders in at 0.19 and 0.18. The way I see it why even bother selling at these ridiculous prices you get nothing... Most people who sold were likely looking for a quick buck. Right now the best thing to do is hold on to your shares and wait as the story develops. Most selling was irrational behaviour, the company is selling at a huge discount, it's like buying an item full price, than saying you don't want it but returning it for a fire sale price. As said before, the baseline has been reset much lower, lawsuit out of the way, a normal Q4, now we will be able to see actual growth of plasma centers going forward. On top of that, now any other catalyst or new signed contracts or new markets will simply be a cherry on top.
E.
The Facts about the Financial Results
As a long time holder I have gotten use to these up and downs in the company's stock and its earnings. I find the results to be mediocre but on the positive side i'm happy because it resets the bar to a normalized level.
To all new or old holders the 2014 Q4 results should not be used as a baseline as many projects had come to an end that quarter (some substantially large ones) and since the company has to recognize the revenue at the end as it signifies completion it significantly inflated 2014FY and Q4 compare to what the company would "typically" do. It also inflated gross margins as the company had incurred most of the expenses for these projects earlier on.
The Positives:
- From conversations I have had and from the results I have seen the company's main revenue stream and focus is the plasma donation centers which is growing (79 to 91 this year and expected to continue to grow further). This is a high growth industry as plasma centers are on the rise in the US and 3Pea's clients themselves are growing which means more revenue for 3Pea (plus many potential new clients to add). I like this revenue stream. Its consistent and predictable and we won't see many of these big yoyo swings in revenues. In my opinion, the company should focus lots of attention on this revenue stream as its worth more, company's with predictable earnings streams trade at higher multiples.
-I took a look at the CAGR(cumulative avg growth rate) from 2011 to 2015 and we are still sitting at 25% (3.3M,6.7M,6.308M,10.293M,8.108M). Similarly, gross income CAGR sits at 47% ( 0.87 1.395 2.204 5.638 4.088). I'd rather look at this as it normalizes the growth.
- Gross margins are trending nicely (back out the artificially high one from last year e are looking pretty good)==> (2012:20.82%; 2013:34.94%; 2014:54.78%; 2015:50.42%)
- Q4 was profitable by a sliver. Here are some stats for the Q4: 2.16M rev, 1.1M Gross income, SG&A was slightly lower than last years Q4 at 0.87M (vs 1M in Q4 2014), operating income of 0.079M.
- Lawsuit is out of the way and was fully taken as a hit to 2015FY (if it was not for that it pretty much would have been an ok year with no loss as it was mainly the legal settlement and fees that hurt both the Cash flow and income statement.
- Valuation is ridiculous: at 42M F/d share float and 0.19$ price the whole company is valued at 8M$ which is less than what they earned in relatively predictable revenue this year which I expect will grow. Sure they are not issuing tons of press releases but they are working on growing the business - they were at the plasma conference in Barcelona - I would take that as they are working hard at expanding within the Plasma segment. shares are trading at barebone valuations because of people's hopes for a quick pop on a Q4 but this is still a developing story - it takes time but this is one catalyst away from a major pop which could really be anything - a new big plasma client, an approval to start business in Europe or some bigger company in the sector that wants to take them out because of how dirt cheap it would be.
I feel 2016 will be a much better year, best of luck to all!
E
WOW23P,
I wouldn't necessarily coincide their sponsorship/attendance to the conference with an entry into the EU.
They did attend last year as well, no sure if they were one of the top sponsors as they were this year but definitely is a good presence for them to have and to get "in" with all the top industry players.
Per the conference website:
PPTA represents over 450 human plasma collection centers in the North America and Europe, as well as, the manufacturers of life saving plasma protein therapies.
Our members produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
It's more of an international presence rather than simply in the EU which is good from how I see it.
E.
Look who Gold Sponsored the recent International Plasma Conference in Spain...
Did some digging online here's what I stumbled on:
http://www.pptaglobal.org/meetings-events/international-plasma-protein-congress
Good things will come - give it time I have faith in management.
Been here almost as long as you Mr.D.
Would not expect as big of a Q4 as last year as it was abnormally large due to revenue recognition of many projects coming to an end but I do expect a consistent ramp up in plasma centers as we have continued to see. Margins should continue to creep up and legal settlement is out of the way.
I would look at the company gaining some pace in the second half of 2016 with the hopes of some traction in other verticals. Quite cheap down here - we are at the bottom of the valuation range - I would expect us to trend towards 0.50 or more if we can get a few good Q's showing traction and regaining the lost momentum. Management is busy with year end I would expect the results in March.
E.
Typically comes Next Month With Year End FY results
From my knowledge, the income statement will not be impacted as they chose to expense it entirely in the past quarter. Margins should hold up well. I would not be expecting a "massive" Q4 like last year. In my opinion it was slightly an irregularity due to many card projects coming to an end in that quarter and the company having to recognize revenue once they come to an end. I do expect continued growth in the plasma sector and I feel this consistent revenue stream is more important and valuable over the long run and is what we should look for.
Although the income statement will likely not be impacted you will see the balance sheet take a slight hit as the future payments will probably be recorded under "payables" with cash also being impacted.
Just my opinion. Still long and strong.
Looks like your extrapolation proved correct - a nice break to the upside with more supportive buying pressure.
Lets hope this keeps up. I loaded up on some at 0.18 and 0.209 over the past weeks.
E.
Looks like many of us picked up shares on Friday.
I also dipped my toes in. I see the current price as a great long-term entry point. Regardless of any future growth opportunities, their plasma business itself warrants a much greater premium than the current company's value (9M market Cap...) The company has traded higher than the current price years back when they had an even smaller plasma presence with no Paysign platform - so take that for what it is.
The lawsuit is in the past and I'm glad they opted to take one large hit rather than contaminate future earnings. Margins keep expanding due to full integration of their Paysign platform and direct sales strategy.
I personally am not expecting anything huge for Q4 but it will likely be reasonable.I have an understanding of how their earnings work and how they are recognized and it would not really phase me if it's lower in revenue than the last Q4 - what I look for is the "normalized" earnings over the long term. I do expect the company to start showing progress over the next year. We sha'll see... I'm a buyer under 0.20.
Best of luck.
E.
Probably tax loss selling, its a steal at these prices (even if we only assume the plasma business growth) however i don't see it coming up sharply until the new year.
**Also to note, I was looking at Q3 revenue trends yoy in S&P Cap. IQ and it is quite a nice linear growth line. 2012: 0.62M ; 2013: 1.06M ; 2014: 1.7M ; 2015: 2.03M which demonstrates the company is growing its core earnings which is principally made up of Plasma center growth. The same is true for gross margins which were below 20% in 2012 and have grown steadily to over 50%.
The way I see it;
I'm happy they took a one time shot with the lawsuit rather than spreading the pain over the long term as it will be better for longer term results.
The continued growth in revenue is at a good consistent pace as they continue to gradually add Plasma Centers. This shapes up the company's earnings and promises more stable cash flow over time rather than the specialty programs that are synonymous with the old "lumpy" revenue.
Gross margins continue to expand due to full integration of the Paysign platform which supports the bottom line.
SG&A were higher than before, however I group SG&A's as "recurring" and "non-recurring", and when I look at the current SG&A number lots of the increase was due to non recurring expenses (if we take a long term view). The legal fees were in this SG&A and since most of this was resolved in October I don't see many more major legal fees being incurred in Q4 and 2016. Secondly, I believe lots of the research, admin and other costs involving the EU have been incurred over the past year and even if they do continue to incur some costs, if they do decide to proceed with it the set-up costs will not be re-curring. (that being said staffing costs would go up but will likely be outweighed by earnings from those operations).
Overall, I'd say its a "decent" quarter if we remove the lawsuit which was already accounted for and expected.
FYI Will Report After Close
It was mentioned in the article (very briefly) saying it was settled for a reasonable amount.
I think the article was good exposure as the company is trading at a meager valuation even in spite of the suit. The business fundamentals have not changed and if anything they have only grown further by adding on more plasma centers, increasing margins and continuing to execute. As the author says, I also see it as an opportunity, since anything under 0.30 I consider to be a gift. I will like to see how the results progressed in Q3 which should be out over the next 2 weeks.
For every seller today there was a buyer... still big volume and some big buying stepping in at these prices.
Earnings last year were reported around Nov. 13th, I would expect close to that again this year so not too long to go. I would no anticipate any update in between but would hope for them to shed light during the Q's release. However, I am not too worried as I know they have been quite busy with many endeavors recently.
Based on TTM revenue we are trading at about a 1 time multiple to our sales quite low given many company's have been taken-out at close to 5 times.
From what I got they don't necessarily want to highlight the bad news through PR's. I'm sure we will get some light shed on it through the Q3 release. I know the plasma business is showing significant growth and keeping them pretty busy and overall things are going well. I'm a buyer at these levels - whats great about these micro-cap stocks is you can capitalize from the low liquidity since the stock gets hammered down way too easily and well below its fundamental value.
I was able to become Mod again and update the info!
Hey Chilar,
I'd update it for you but it seems my lack of posts has kicked me out of being moderator.
IF you could simply delete the old CFO part under "management team" and add Brian as (interim CFO)
They've already paid the 1M, the 1.5M is over 18 months so 83k/month.. really not that bad. They had nearly 3M in cash last quarter. They will be fine.
Good post Mr. D. I fully agree (I have nothing but great things to say about Brian) and have been a holder for many years here.
I have added a bit at 0.30. I believe its a great opportunity.
GLTA.
If that's the case for the prior CFO, then i'm happy he's gone and that might be the reason the company "canned him" but said he resigned. (He was a partner and founder of another accounting firm at the same time so was not that influential)
I can say from personal experience that Brian (interim CFO) is a very genuine and shareholder friendly company rep. He has been very keen and transparent on taking shareholder questions over the past few years.
Settlement, alright not a big fan of that one time hit but it was settled for much less than the initial amount and a good chunk of it is on a monthly basis (with a decent amount upfront). That being said, the company has been performing well and is gradually growing its customer base so this might be a good opportunity to capitalize on this fear which may simply be a small obstacle to surmount in the grand scheme of things.
E
Q2 2015 Revenue Up 87% to $2.3M; Drives Net Income of $0.5M and Diluted EPS of $0.01
3PEA International, Inc. (“3PEA” or the “Company) (TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, reported financial results for the second quarter ended June 30, 2015.
Q2 2015 Highlights
Revenues increased 87% to $2.3 million compared to $1.2 million in the same year-ago quarter.
Gross profit increased to $1.3 million, or 57.6% of total revenue, compared to $0.5 million, or 43.0% of total revenue in the same year-ago quarter.
Net income increased to $0.5 million, or $0.01 per diluted share, compared to a net loss of $(0.1) million, or $(0.00) per diluted share in the same year-ago quarter.
Increased presence in the plasma donation payments space by adding four new centers in the quarter. Currently, the Company provides payment services to 88 plasma donation centers. 3PEA expects revenues from these centers to increase as they mature.
Management Commentary
“The increases in both revenue and net income in the second quarter was a primarily a result of growth in our corporate incentive prepaid solutions, particularly in plasma donation payment services,” said Arthur De Joya, Chief Financial Officer of 3PEA International. “More importantly, we grew our overall margins as a result of continued traction in plasma, our move to an internal sales force and successfully transitioning our programs onto the PaySign platform. As a result, we expect margins to improve year-over-year, as we add new corporate incentive programs with more profitable and predictable revenue streams in our targeted verticals including plasma donation, automotive and hospitality.”
“We have also developed the most robust sales pipeline in our company’s history and remain focused on expanding our product offerings. Looking ahead, we anticipate an acceleration in our business, while ultimately increasing shareholder value.”
Q2 2015 Financial Results
Total revenues in the second quarter of 2015 increased 87% to $2.3 million, compared to $1.2 million in the same year-ago quarter. This increase was primarily due to growth and maturation in corporate incentive reward programs for plasma centers, and to a lesser extent, revenues associated with specific program life cycle events.
Gross profit in the second quarter of 2015 increased to $1.3 million, or 57.6% of total revenues, compared to $0.5 million, or 43.0% of total revenues in the year-ago quarter. This improvement was attributable to continued growth in plasma card programs, which carry a higher gross margin than pharmaceutical programs, in addition to higher margin revenue as a result of the Company successfully transitioning 100% of its programs onto the PaySign platform.
Total operating expenses in the second quarter of 2015 were $0.9 million, compared to $0.6 million in the year-ago quarter. The increase was primarily due to the Company’s planned expansion into the European Union, as well as increased investments in compliance and customer service personnel.
Net income in the second quarter of 2015 was $0.5 million, or $0.01 per diluted share, compared to a net loss of $(0.1) million, or $(0.00) per diluted share in the year-ago quarter.
At June 30, 2015, the company’s cash balance totalled $2.8 million, compared to $3.9 million at December 31, 2014. At June 30, 2014, the Company had $0.7 million in total debt.
I'll tell you what I make of this...
1) As was mentioned in articles and by the company in past instances, revenue is "lumpy". I will give you that it is quite light of a quarter but I would not make too much of this unless the company had 3-4 consecutive light quarters. Why? I will refer you to a very old filling (Q1 2013) where the company itself said:
"Our revenues and cost of revenues from our pharmaceutical marketing cards fluctuate widely due to a variety of factors beyond our control. The pharmaceutical companies often do not distribute the debit cards via their pharmaceutical sales representatives to various end points for distribution until days, weeks or months after they create a program, often with little advance warning to us. We also experience dramatic usage swings based on collateral marketing efforts by the pharmaceutical companies that run in association with one of our card programs. Constant variations in program start and stop dates, variations in program timelines which range anywhere between six and thirty six months, and variations in program characteristics such as the monetary value of the load, all contribute to provide dramatic swings in the revenue generated from the programs. As a result, our revenues and cost of revenues do no correlate neatly to the number of cards in circulation or even the number of programs that are active at any given time."
- with that said, the quote above simply refers to the pharmaceutical programs however, it can easily apply to other corporate programs. The company only records its revenues once the service has been fulfilled which in most instances means it must realize the majority of its revenues from these programs in the quarter when these programs end. Hence the reason for Q4 being so high, as many programs likely came to an end in that quarter and from my own interpretation may also be the reason for seasonally higher costs in some quarters as costs may be incurred for the start up costs of a program while the majority of revenues may be recorded in a further quarter. (causing larger margins in some quarters over others).
- I don't see this lower quarter as a bad thing, some quarters may have more programs recognizing their revenue than others and this is normal. As well, the first half of the year from what I know is typically seasonally slow even for the "smoother" revenue streams coming from the plasma centers due to colder/harsher weather impeding the customer flow at these centers.
2)I do not expect any material earnings coming from Europe for at least the next 6 months.
Per the company's comments "We have also identified large scale opportunities in the European Union and are aggressively pursuing those opportunities."
- Opportunities are identified and being pursued, nothing is set in stone yet from what I interpret. From what I know about the payment processing industry and breaking into new markets is it's not that simple. The payment processing industry is heavily regulated and there are many hoops you need to jump through to be able operate in new markets. (likely the reason the company has been "pursuing" these opportunities for quite some time.) I personally think the company is making good strides forward in terms of updating their platform, attending international conferences and expanding their service offerings. We may see something come to fruition in the 2016FY and it could be quite a breakthrough if they do expand into a full new market.
3)It is very hard to project earnings for 3Pea due to the many factors affecting their revenues. I would have to see more consistency to be able to properly model their revenue. However, lets just say they do 0.07 eps for the whole year I had already taken the avg p/e in the payment processing industry to be around 36 placing a share price of 2.52$. At these prices take a worst case scenario of a 0.05 eps and place a discounted p/e of 20 and you'll get 1$... not too bad from 0.40$.
What I see going forward and based on current financials:
- Higher "stable" earnings base going forward which will be more consistent over the long term coming from the growth in plasma centers and the auto industry clients.
- Higher core earning margins as the company is bringing everything in house cutting out the middleman profit cut and managing cost more efficiently.
- Stronger financial profile; ie: currently total liabilities to total assets has dropped to 73% from nearly 100% in Q1 2014; current ratio increasing to 1.2 from 0.90 last year. A/P largely down with cash up over the same period last year with the company paying off about 3/4 of a million in high interest long term debt.
- Many catalyst could easily pop up due to 3Pea's expansion in various market segments and the potential to hit a contract with a major client or an expansion into new markets...
Anyways thats my 2 cents, for any other questions I suggests calling up 3Pea's IR. Hope this helps & Happy investing!
E.
Keep Selling - I'm loading up...
To be honest I'm quite happy to see the stock back down here. I never thought I'd have a chance to buy at these prices again.
I have been following the company closely for a few years and am quite use to their swing in revenues/profits. Its "lumpy" due to the way revenue is recognized (no its not manipulative accounting - its simply the nature of some of their card programs).
Of course the company has been gradually moving towards making their earnings much "smoother" with more consistent streams such as ramping up the plasma centers, expanding into the auto dealers etc.. However this is not a change that makes itself over night, its gradual. (albeit even these industries have their seasonality but will be much less than what has been seen).
I have seen them swing high and low looking back at past quarters in prior years, some quarters or even some years showed the realization of large revenue being recognized, others not so much... that's just the way it is... What I look for is the long term prospects of the company, all that matters to me is that this entity keeps growing its customer base, branches out into new service offerings with more customized platforms, continues to improve its margins by bringing more things "in house" (as they have done with the call centre and sales division" and an eventual expansion into a whole new market could be a material game changer...
This price is pretty much close to where we started not so long ago, however since then lots has changed - a little bit of a roller coaster ride - but i'm riding this baby back up!
Exec's hold over 70% - Have Not Sold a thing!
That should clear up any confusion. Our exec's are in it for the long haul and see the value. I can't delete the old msg as its been posted for over 48 hours.
E.
This is simply the start, as it was said "the dominos" have been lined up, all it takes is for them to be knocked down one by one.
The auto sector is MUCH larger than the plasma donation centers and there is ample opportunities to come. The fact that they got their platform into one Hyundai dealership is a stepping stone. If one Hyundai dealer likes it, the platform will sell itself through word of mouth... one dealer will become many more. Obviously this is just Hyundai, all the other dealers of various car makes are potential sales targets.. with the proven testimonial of dealers already using the platform, 3Pea's expansion has lots of room to run...
That's simply the auto dealer side... PaySign is quite versatile and can be expanded into multiple different industries.
The company is still in quite an infancy stage, there is lots of potential to go however, I would not be surprised to see these guys taken out at 5$+/share in 2-3 years time.
E.
Your guys can email me at b-wright.erik@hotmail.com - I have the slides
Presentation is not on the website but I have touched base with Dallas, the author of the most recent article that he obtained it from Greg, their IR contact at MZ. I have emailed Greg to obtain a copy and can send it to others on the board, just PM me your email.
Cheers,
E.
Looking better and better for 3PEA!
I don't think Q1 or Q2 will be too material but I can definitely see the second half of the year showing much stronger earnings due to developments over the year, new signings, plasma ramp ups, product offering expansion, etc...
IMO FYE2015 to Beg. 2016 will see us trade in the above 1$ range...
3PEA - Micro Cap Opportunity Article/Warrant Comments
For everyone's info see below (a great highlight of the events over the past year along with potential Catalysts to come):
MicroCap Opportunity - Why Does 3Pea Look So Interesting?
FYI Zenvesting see the response that has been posted regarding your warrant concerns:
"Thanks for your interest Zenvesting! We believe that Q4 is likely a little higher than the "normalized" quarterly earnings. Likely due to lots of project-specific revenue being recognized. We don't expect Q1 to be as big, but do expect it to be showing some growth coming from the additional plasma donor centers that the company has been growing nicely over the past years. As for the warrants, we don't see it as too much of an issue. If not exercised by May 31st will be rendered worthless, if they are exercised 3Pea will get a nice little cash injection to help them further expand. The fact that they bought back 2.44M shares somewhat cancels out most of the dilution that would come from warrants being exercised. The company could really use a bigger public float as most shares are very tightly held by long time holders with another 72% owned by management. Anyways, best of luck and happy investing!"
Great Article ~
See below - summarizes the key catalyst for 3PEA going forward as well as what makes the company stand out given the latest years events:
Seeking Alpha TPNL - Micro Cap Opportunity Article
I believe we will see great things to come from 3PEA going forward and that this is just the start for our little friend!
E.